---
figid: PMC9600774__cancers-14-05099-g012
pmcid: PMC9600774
image_filename: cancers-14-05099-g012.jpg
figure_link: /pmc/articles/PMC9600774/figure/cancers-14-05099-f012/
number: Figure 12
figure_title: ''
caption: Compound C re-sensitizes cisplatin-resistant patient-derived OvCa cells to
  cisplatin. (A) Schema of isolation and maintenance of patient derived OvCa cells.
  (B) IC50 values of AF1, OM1, AF2 and OM2 cells, showing the effect of CC and cisplatin
  in mono- and combination therapy on ascitic fluid-derived (AF) and matching omentum-derived
  (OM) cells. (C) Table insets show the combination indices (CI) and the effective
  doses of combinatorial therapy of CC and cisplatin.
article_title: Compound C Inhibits Ovarian Cancer Progression via PI3K-AKT-mTOR-NFκB
  Pathway.
citation: Alia Ghoneum, et al. Cancers (Basel). 2022 Oct;14(20):5099.
year: '2022'

doi: 10.3390/cancers14205099
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI

keywords:
- ovarian cancer
- compound C
- PI3K
- AKT
- mTOR
- NFκB
- platinum-resistance

---
